MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Ligand Pharmaceuticals Inc

Suletud

SektorTervishoid

108.37 2.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

102.24

Max

109.04

Põhinäitajad

By Trading Economics

Sissetulek

-24M

-31M

Müük

-9M

43M

P/E

Sektori keskmine

47.016

57.333

Aktsiakasum

1.27

Kasumimarginaal

-72.615

Töötajad

68

EBITDA

-33M

-30M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+40.57% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-42M

2B

Eelmine avamishind

105.95

Eelmine sulgemishind

108.37

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Ligand Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Intel, AppFolio

24. apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. apr 2025, 23:37 UTC

Peamised uudised

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. apr 2025, 23:36 UTC

Peamised uudised

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. apr 2025, 23:13 UTC

Peamised uudised
Tulu

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. apr 2025, 23:09 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. apr 2025, 22:51 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 22:48 UTC

Peamised uudised

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. apr 2025, 22:38 UTC

Market Talk
Tulu

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. apr 2025, 22:24 UTC

Market Talk
Tulu

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. apr 2025, 22:23 UTC

Tulu

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. apr 2025, 22:11 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

24. apr 2025, 22:11 UTC

Market Talk
Tulu

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. apr 2025, 22:09 UTC

Peamised uudised
Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. apr 2025, 22:00 UTC

Market Talk
Tulu

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. apr 2025, 21:39 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. apr 2025, 21:24 UTC

Peamised uudised
Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 21:24 UTC

Peamised uudised
Tulu

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. apr 2025, 21:23 UTC

Peamised uudised
Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. apr 2025, 21:04 UTC

Tulu

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. apr 2025, 21:02 UTC

Tulu

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Võrdlus sarnastega

Hinnamuutus

Ligand Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

40.57% tõus

12 kuu keskmine prognoos

Keskmine 148.67 USD  40.57%

Kõrge 160 USD

Madal 135 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ligand Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

104.86 / 106.345Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.